CLINICAL TRIALS PROFILE FOR INDOMETHACIN
✉ Email this page to a colleague
All Clinical Trials for INDOMETHACIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000494 ↗ | Management of Patent Ductus in Premature Infants | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1978-09-01 | To evaluate the effects (up to one year of age) of indomethacin on the clinical course of patent ductus arteriosus (PDA) in premature infants (24 hours old or less) and to assess the relative merits of indomethacin and surgery in infants with persistent respiratory distress who were not treated early with indomethacin. Two concurrent trials were performed. |
| NCT00002535 ↗ | Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | Completed | St. Luke's Medical Center | Phase 2 | 1993-07-01 | RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of indomethacin and biological therapy with or without cyclophosphamide in treating patients who have advanced melanoma that has not responded to previous therapy. |
| NCT00002796 ↗ | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | Terminated | National Cancer Institute (NCI) | Phase 1/Phase 2 | 1997-05-01 | Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon-gamma may interfere with the growth of tumor cells and slow the growth of the tumor. Combining more than one drug with interferon-gamma may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of giving fluorouracil together with phenylbutyrate, indomethacin, and interferon-gamma and to see how well it works in treating patients with stage IV colorectal cancer |
| NCT00004778 ↗ | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery | Completed | Children's Hospital of Philadelphia | Phase 3 | 1993-08-01 | OBJECTIVES: I. Evaluate the effect of thyrotropin-releasing hormone (TRH) on the severity of initial lung disease and occurrence of chronic lung disease when given antenatally to women with threatened premature delivery. II. Evaluate possible mechanisms for the effects of TRH on the severity and incidence of chronic lung disease. III. Investigate whether a deficiency in endogenous cortisol and/or thyroid hormones after birth influences the severity of lung disease and the development of chronic lung disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for INDOMETHACIN
Condition Name
Clinical Trial Locations for INDOMETHACIN
Trials by Country
Clinical Trial Progress for INDOMETHACIN
Clinical Trial Phase
Clinical Trial Sponsors for INDOMETHACIN
Sponsor Name
